Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Boston Scientific ( (BSX) ) just unveiled an announcement.
Boston Scientific Corporation has announced the resumption of its AVANT GUARD clinical trial, focusing on drug-naïve patients with persistent atrial fibrillation. This decision follows a thorough assessment and collaboration with the study’s data monitoring committee, signaling potential advancements in treatment options for this patient group.
Find detailed analytics on BSX stock on TipRanks’ Stock Analysis page.